Loading
A phase 1/2 trial of Fulvestrant in endometrial cancer and ovarian cancer, run by Terremoto Biosciences Inc., now recruiting.
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations is a phase 1/2 interventional study registered as NCT07109726 by Terremoto Biosciences Inc., with 205 participants planned, started 2025-09-23 and due to reach its primary completion in 2028-12-30. Interventions recorded: TER-2013, Fulvestrant injection. Conditions listed: Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulvestrant, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/